The modest EPS beat is unlikely to move the stock materially for a pre-revenue biotech. The activist 13D filings from two directors (So and Glavine) who each received ~28% withhold votes suggest internal governance pressure. Monitor for any activist-driven strategic alternatives, partnership announcements, or pipeline milestones for HLP003 Phase 3 data.
Price Chart
Executive Summary
Helus Pharma (HELP) reported Q1 2027 EPS of -$0.91, a 3.7% beat vs consensus of -$0.94, on zero revenue. The filing also covers shareholder meeting results approving a name change to Helus Pharma Inc. and election of directors, with notable 28% withhold votes for four directors. The EPS beat is modest for a pre-revenue clinical-stage biotech, and the name change signals commercial readiness, but the activist cross-filing context (two SC 13Ds filed 13 days ago) adds pressure for strategic action.
Key Financial Metrics
Key Facts
- Q1 2027 EPS of -$0.91 beat consensus of -$0.94 by 3.7%
- Revenue was $0 (pre-revenue clinical-stage company)
- Shareholders approved name change from Cybin Inc. to Helus Pharma Inc., effective October 1, 2026
- Two SC 13D filings from Eric So and Paul Glavine were filed 13 days prior, indicating activist interest
- Four directors received ~28% withhold votes, suggesting shareholder dissent
- Lead program HLP003 is in Phase 3 for major depressive disorder with Breakthrough Therapy Designation
Financial Impact
EPS beat of $0.03 per share on a -$0.94 consensus, representing a 3.7% positive surprise; no revenue to evaluate
Risk Factors
- Pre-revenue company with no approved products; cash burn continues
- Activist 13D filings may signal board conflict or push for sale/restructuring
- 28% withhold votes for four directors indicate shareholder dissatisfaction
- Phase 3 clinical risk for HLP003; regulatory and commercial execution uncertainty
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3366911 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 3 | $10.11 | awaiting T+20 | — | $10.36 (+2.47%) |
Oct 26, 2026 today | 3 | $10.86 | awaiting T+20 | — | $10.36 (−4.56%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 21, 2026 5d ago | 6-K | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 15, 2026 11d ago | 6-K | $11.05 | awaiting T+20 | — | $10.36 (−6.24%) |
Oct 15, 2026 11d ago | Press Release | $11.05 | awaiting T+20 | — | $10.36 (−6.24%) |
Oct 8, 2026 18d ago | 6-K | $10.72 | awaiting T+20 | — | $10.36 (−3.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers